MTEM Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases...

Stats
Šios dienos apimtis	68 803.00
Vidutinė apimtis	64 717.00
Rinkos kapitalizacija	9.16M
EPS	$0 ( 2024-04-04 )
Kita pelno data	( $-0.970 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.950
ATR14	$0.0330 (1.94%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-02	Biotech Target N V	Buy	250 000	Common Stock
2024-04-02	Biotech Target N V	Buy	769 334	Common Warrants (right to buy)
2024-04-02	Biotech Target N V	Buy	134 667	Prefunded Warrants (right to buy)
2024-04-02	Lalande Kevin M.	Buy	1 154 154	Warrants (Right to Buy)
2024-04-02	Lalande Kevin M.	Buy	402 077	Pre-Funded Warrants (Right to Buy)

INSIDER POWER
99.93
Last 98 transactions
Buy: 16 322 736 \| Sell: 222 785

Tūris Koreliacija

Ilgas: 0.01 (neutral)

Trumpas: -0.59 (weak negative)

Signal:(58.538) Neutral

Molecular Templates Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Molecular Templates Inc Koreliacija - Valiuta/Žaliavos

-0.33
( neutral )

-0.45
( neutral )

0.00
( neutral )

-0.38
( neutral )

0.41
( neutral )

0.32
( neutral )

Molecular Templates Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$57.31M
Bruto pelnas:	$50.40M (87.94 %)
EPS:	$-1.800

FY	2023
Pajamos:	$57.31M
Bruto pelnas:	$50.40M (87.94 %)
EPS:	$-1.800

FY	2022
Pajamos:	$19.75M
Bruto pelnas:	$11.95M (60.51 %)
EPS:	$-24.69

FY	2021
Pajamos:	$38.70M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$1.690

Financial Reports:

No articles found.

Molecular Templates Inc

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.